KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Net Margin: 2017-2025

Historic Net Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to 2.31%.

  • Amneal Pharmaceuticals' Net Margin rose 64.00% to 2.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.96%, marking a year-over-year increase of 762.00%. This contributed to the annual value of -4.18% for FY2024, which is 67.00% down from last year.
  • Amneal Pharmaceuticals' Net Margin amounted to 2.31% in Q3 2025, which was down 52.98% from 4.92% recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Net Margin high stood at 4.92% for Q2 2025, and its period low was -21.60% during Q2 2022.
  • Its 3-year average for Net Margin is -1.28%, with a median of 1.67% in 2024.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Net Margin slumped by 2,431bps in 2022 and then spiked by 2,359bps in 2023.
  • Amneal Pharmaceuticals' Net Margin (Quarterly) stood at -1.19% in 2021, then soared by 48bps to -0.71% in 2022, then crashed by 1,528bps to -15.99% in 2023, then soared by 1,314bps to -2.84% in 2024, then surged by 64bps to 2.31% in 2025.
  • Its Net Margin was 2.31% in Q3 2025, compared to 4.92% in Q2 2025 and 3.54% in Q1 2025.